Evidence map›Paper›PMID 38313517›Full record

ArticleACS omega2024

QbD-Assisted Development and Optimization of Doxycycline Hyclate- and Hydroxyapatite-Loaded Nanoparticles for Periodontal Delivery.

Pooja Jain, Mohd Aamir Mirza, Enam Reyaz, Mirza Adil Beg, Angamuthu Selvapandiyan, Nazeer Hasan, Akbar Naqvi, Naseef Punnoth Poonkuzhi, Mohammad Saheer Kuruniyan, Harlokesh Narayan Yadav and 2 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Pooja JainDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, SPER, Jamia Hamdard, New Delhi 110062, India.
Mohd Aamir MirzaDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, SPER, Jamia Hamdard, New Delhi 110062, India.ORCID https://orcid.org/0000-0002-5780-7601
Enam ReyazDepartment of Molecular Medicine, Jamia Hamdard, New Delhi 110062, India.
Mirza Adil BegDepartment of Molecular Medicine, Jamia Hamdard, New Delhi 110062, India.
Angamuthu SelvapandiyanDepartment of Molecular Medicine, Jamia Hamdard, New Delhi 110062, India.ORCID https://orcid.org/0000-0002-2194-1534
Nazeer HasanDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, SPER, Jamia Hamdard, New Delhi 110062, India.
Akbar NaqviDepartment of Dentistry, HIMSR, New Delhi 110062, India.
Naseef Punnoth PoonkuzhiDepartment of Pharmaceutics, Moulana College of Pharmacy, Perinthalmanna, Kerala 679321, India.ORCID https://orcid.org/0000-0001-9692-6323
Mohammad Saheer KuruniyanDepartment of Dental Technology, COAMS, King Khalid University. Abha 61421, Saudi Arabia.
Harlokesh Narayan YadavDepartment of Pharmacology, AIIMS, New Delhi, 110608, India.
Farhan J AhmadDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, SPER, Jamia Hamdard, New Delhi 110062, India.ORCID https://orcid.org/0000-0002-0740-8573
Zeenat IqbalDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, SPER, Jamia Hamdard, New Delhi 110062, India.ORCID https://orcid.org/0000-0003-2788-9420
Jamia Hamdard · INAll India Institute of Medical Sciences Raipur · INKing Khalid University · SAMoulana Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current research aims to develop a carrier system for the delivery of a matrix metalloproteinase (MMP) inhibitor along with a bioceramic agent to the periodontal pocket. It is proposed that the present system, if given along with a systemic antibiotic, would be a fruitful approach for periodontitis amelioration. To fulfill the aforementioned objective, a doxycycline hyclate- and hydroxyapatite-adsorbed composite was prepared by a physical adsorption method and successfully loaded inside sodium alginate-chitosan nanoparticles and optimized based on particle size and drug content. Optimized formulation was then subjected to different evaluation parameters like encapsulation efficiency, hydroxyapatite content, ζ potential, surface morphology, in vitro drug release, cell line studies, and stability studies. For the optimized formulation, particle size, polydispersity index (PDI), entrapment efficiency, ζ potential, and drug content were found to be 336.50 nm, 0.23, 41.77%, -13.85 mV, and 14.00%, respectively. The surface morphology of the placebo and adsorbed composite-loaded nanoparticles as observed by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) revealed the spherical shape and rough surface of the particles. In gingival crevicular fluid (GCF) 7.6, a sustained drug release profile was obtained up to 36 h. In vitro % viability studies performed on murine fibroblast cells (NIH3T3) and human periodontal ligament (hPDL) cell lines confirmed the proliferative nature of the formulation. Also, when subjected to stability studies for 4 weeks, particle size, PDI, and drug content did not vary considerably, thereby ensuring the stable nature of nanoparticles. Henceforth, sodium alginate-chitosan nanoparticles appeared to be a good carrier system for doxycycline hyclate and hydroxyapatite for periodontal therapy. If given along with a system antibiotic, the system will serve as a fruitful tool for infection-mediated periodontal regeneration and healing.

Identifiers

PMID38313517
PMCPMC10831838
OpenAlexW4391004779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.